2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Esanex Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SNX-5422 in TP53 Null Cancers SNX-5422 - Cancer | Phase 2 | Terminated | Esanex Inc. | 1 | 2016-03-01 | 2018-11-14 |
| Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers SNX-5422 - Cancer | Phase 1 / Phase 2 | Terminated | Esanex Inc. | 15 | 2013-04-01 | 2017-02-09 |
Neoplasms (2)
SNX-5422 (2)
United States (2)